Introduction
Toll-like receptors (TLRs) recognize molecules derived from pathogens as well as endogenous danger signals possessing similar chemical structures (1) (2) . Recently, functional TLRs were found to be expressed in cancer cells but their significance remains controversial (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Whereas most of the therapeutic strategies using microbial products were designed with the idea of activating TLRs present on innate immune system cells (3) (4) (5) (6) (7) (8) (9) (10) , clear distinction about the separate contribution of immune and cancer cells to the immune response has yet to be done. Stimulation of TLR4, the main receptor of bacterial lipopolysaccharide (LPS), on tumor cells has been shown to have a positive role in tumorigenesis in in vivo (13) (14) (15) , but mainly in in vitro settings (16) (17) (18) (19) . When tumor expression of TLR4 or the adaptor molecule MyD88 was inhibited in tumor cells themselves, opposite conclusions were observed. This suggests a more complex scenario and that the consequences of TLR4 triggering on tumor cells could depend on the type of tumor, the way TLR4 is activated, if such activation is sustained in time, as it would be in the case of chronic activation by endogenous ligands or if it is the result of an acute process (20) (21) (22) (23) (24) .
Stimulating MAT-LU, a rat prostate adenocarcinoma cell line, with LPS in vitro, before inoculation, produced significant inhibition of tumor growth in Copenhagen rats (24) (25) .
The same effect was observed when B16 melanoma cells, were stimulated for 48h in vitro with LPS or Monophosphoryl Lipid A prior to its inoculation into syngeneic mice. This in vivo inhibition of tumor growth depends exclusively on TLR4 present on tumor cell themselves and not on antigen presenting cells from the host, since it was not observed in TLR4 deficient mice (TLR4 lps-del ) (24) . When LPS-stimulated B16 or MAT-LU cells were inoculated into nude mice, the growth of tumors elicited did not significantly differ from tumors induced by non-stimulated B16 or MAT-LU cells, indicating that the T cell compartment was required (24) .
These findings prompted us to determine which molecular and cellular mechanisms might be involved in this phenomenon. We have identified interferon ȕ, produced by TLR4-activated tumor cells as an important mediator of these effects. Our work brings in a novel aspect to discuss: under specific conditions and, probably, at specific moments of tumor development, TLR4 triggering on tumor cells could positively help the cross-talk between tumor and immune cells, favoring an antitumoral immune response. Irf1), mainly IFN beta (120x) was observed (Fig.1A) . This up-regulation of IFN beta expression levels was confirmed by qRT-PCR using a different set of primers (Fig.1B) .
RESULTS

Triggering
The up-regulation of IFNbeta mRNA expression levels was also observed in two other murine tumor cell lines expressing TLR4: the MB49 and TRAMPC2 cells (Supp. Fig.1A ).
Both cell lines generated smaller tumors once activated via TLR4, prior to their in vivo inoculation in TLR4
lps-del and C57BL/6 mice. (Supp. Fig.1B and C) . In the case of the TRAMPC2 prostate cancer model, the inhibition of tumor growth observed was not statistically significant, but the incidence of tumor bearing animals was lower in the LPSgroup (Supp. Fig.1C ). Low levels of secreted IFNβ could also be reliably measured by ELISA in LPS-activated tumor cells (Fig. 1B and Supp. Other genes were extremely down regulated in both experimental groups subjected to tumor supernatants (like Csf2 and Csf3). In contrast, differences were found in the expression of certain genes among the three experimental groups. When transcription of genes of the NFkB complex was evaluated, only TLR4
lps-del BMDCs matured in the presence of LPS-B16 CM showed a significant increase (x380 NFkb1, x468 Rela), indicating a more sustained or stronger stimulation of the cells. Reasonably, a strong increase in transcription levels of both inhibitor molecules such as NFkBia (IkBalpha) and NFkBib (IkBbeta) was also observed (x80 and x1250 compared to x33 and x375 in B16-CM). Interestingly, the expression of IL12a that was inhibited in DCs incubated with B16-CM (x1.8) was partially restored when LPS-B16 CM (x5) was present at the time of maturation.
Next, we examined the ability of B16-CM and LPS-B16 CM to modulate cytokine secretion by DCs. As expected, immature DCs (iDCs) exposed to CpG showed a significant increase in IL-12p40 secretion (Fig. 2B) . A 5-fold reduction in IL12p40 secretion was observed when iDCs were simultaneously incubated with B16-CM and CpG for 24h. This reduction was not due to an expansion of Gr1+CD11c+ at the expense of CD11c+ cells, since the exposure of the iDCs for 24h to CM did not alter the final phenotype of the cells (Supp. Fig. 2A and B) . In contrast, IL12p40 secretion levels were partially restored when the cells were incubated with LPS-B16 CM (3-fold reduction, p<0.05) (Fig.2B ). Similar results were observed when IL12p70 levels were evaluated: even though CpG alone is a poor inducer of IL12p70 (32), detectable levels of IL12p70 could be reliably measured in TLR4 lps-del DCs exposed to CpG (Fig. 2B and Supp. Fig. 2C ). These levels were almost abrogated when TLR4 lps-del DCs were incubated with B16-CM, LPS-B16 CM and B16-CM plus CpG. In contrast, IL12p70 was partially restored when TLR4 lps-del DCs were matured with CpG in the presence of LPS-B16 CM (Fig. 2B and Supp. Fig. 2C ). When TNFĮ 
bearing LPS-B16 tumors (Fig.2C) . This experiment also suggests that DCs, one of the most prolific producers of these cytokines could be involved in the inhibition of tumor growth observed in our in vivo model. (Fig.3A and Supp. Fig.3 ).
LPS-
Spleen CD11c+ cells from all tumor-bearing animals showed an activated phenotype, with a higher percentage of cells expressing increased levels of MHC class II and costimulatory molecules (Fig.3B ). However, a further enhancement in the expression levels of CD40, CD80 and, in some experiments of CD86 was observed in CD11c+ cells from animals bearing LPS-B16 tumors ( Fig.3B and C) .
Intratumoral infiltrating mononuclear cells were also analyzed. Although the percentage of CD11c+ cells in LPS-B16 tumors did not change (Fig.3A) , the frequency of IL12+
CD11c+ cells (Fig.3D ) was increased. Moreover, when tumor infiltrating mononuclear cells were stimulated ex-vivo with PMA-ionomycin for 5h and IFNȖ-IL10 cytokine intracellular staining was performed, an increased frequency of IFNγ+ CD3+ cells was observed in LPS-B16 tumors compared to B16 tumors. The opposite was observed when IL10+ CD3+ cells were analyzed ( Fig.3E and F) . 
Thus, LPS-B16 cells inoculated into TLR4
lps-del mice promote a better functionality of DCs in vivo, which could be associated with a more efficient Th1 response in situ and the reduced tumor growth observed. that type I IFN signaling is involved in tumor growth inhibition induced by activation of TLR4 expressed on tumor cells (Fig.4C) . To observe if IL-28 (a distinct category of type I-like IFN, also referred to as type III IFN) (34) could be playing a role in tumor inhibition in our model, we inoculated B16 cells stimulated or not with LPS in IL-28R KO mice.
IFNȕ
Inhibition of tumor growth was observed in wild type mice but only a partial and nonstatistically significant inhibition of tumor growth was seen in the IL-28R KO mice, indicating that type III IFNs could also be playing a role in the phenomenon (Fig. 4D) . 
